Cutting edge: Tumor-targeting antibodies enhance NKG2D-mediated NK cell cytotoxicity by stabilizing NK cell-tumor cell interactions

Journal of Immunology

Volumn 189, Issue 12, 2012, Pages 5493-5497

  Deguine, Jacques ^a,b   Breart, Béatrice ^a   Lemaître, Fabrice ^a   Bousso, Philippe ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D;

ANIMAL CELL; ANTIBODY DETECTION; ANTIGEN RECOGNITION; ARTICLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL KILLING; CONTROLLED STUDY; DEGRANULATION; DRUG TARGETING; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR CELL;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL COMMUNICATION; CELL DEGRANULATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GENE KNOCK-IN TECHNIQUES; KILLER CELLS, NATURAL; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IGG; THYMOMA; UP-REGULATION;

EID: 84871116894     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202065     Document Type: Article

References (22)

1. Scott, A. M., J. D. Wolchok, and L. J. Old. 2012. Antibody therapy of cancer. Nat. Rev. Cancer 12: 278-287.
2. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758. (Pubitemid 34525533)
3. Ferris, R. L., E. M. Jaffee, and S. Ferrone. 2010. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 28: 4390-4399.
4. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
5. Gluck, W. L., D. Hurst, A. Yuen, A. M. Levine, M. A. Dayton, J. P. Gockerman, J. Lucas, K. Denis-Mize, B. Tong, D. Navis, et al. 2004. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin. Cancer Res. 10: 2253-2264. (Pubitemid 38445682)
6. Berdeja, J. G., A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn. 2007. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin. Cancer Res. 13: 2392-2399. (Pubitemid 46698589)
7. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274. (Pubitemid 40563170)
8. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526. (Pubitemid 32928761)
9. Diefenbach, A., E. R. Jensen, A. M. Jamieson, and D. H. Raulet. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171. (Pubitemid 32867877)
10. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, and D. H. Raulet. 2008. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
11. Routes, J. M., S. Ryan, K. Morris, R. Takaki, A. Cerwenka, and L. L. Lanier. 2005. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J. Exp. Med. 202: 1477-1482. (Pubitemid 41746594)
12. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190. (Pubitemid 41232299)
13. Bryceson, Y. T., M. E. March, H.-G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166. (Pubitemid 43053538)
14. Deguine, J., B. Breart, F. Lemaître, J. P. Di Santo, and P. Bousso. 2010. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity 33: 632-644.
15. Breart, B., F. Lemaître, S. Celli, and P. Bousso. 2008. Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J. Clin. Invest. 118: 1390-1397. (Pubitemid 351500432)
16. Gazit, R., R. Gruda, M. Elboim, T. I. Arnon, G. Katz, H. Achdout, J. Hanna, U. Qimron, G. Landau, E. Greenbaum, et al. 2006. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7: 517-523.
17. Vasovic, L. V., R. Dyall, R. A. Clynes, J. V. Ravetch, and J. Nikolic-Zugic. 1997. Synergy between an antibody and CD8+ cells in eliminating an established tumor. Eur. J. Immunol. 27: 374-382. (Pubitemid 27085240)
18. Wood, S. M., M. Meeths, S. C. Chiang, A. G. Bechensteen, J. J. Boelens, C. Heilmann, H. Horiuchi, S. Rosthøj, O. Rutynowska, J. Winiarski, et al. 2009. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood 114: 4117-4127.
19. Rechavi, O., I. Goldstein, and Y. Kloog. 2009. Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Letters 583: 1792-1799.
20. Caramalho, I., M. Faroudi, E. Padovan, S. Müller, and S. Valitutti. 2009. Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumor cell annihilation. J. Cell. Mol. Med. 13: 3834-3846.
21. Inagaki, A., T. Ishida, H. Yano, T. Ishii, S. Kusumoto, A. Ito, M. Ri, F. Mori, J. Ding, H. Komatsu, et al. 2009. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int. J. Cancer 125: 212-221.
22. Kellner, C., D. Hallack, P. Glorius, M. Staudinger, S. Mohseni Nodehi, M. de Weers, J. G. J. van de Winkel, P. W. H. I. Parren, M. Stauch, T. Valerius, et al. 2011. Fusion proteins between ligands for NKG2D and CD20-directed singlechain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26: 830-834.